Table 1. Patient characteristics and comparison between those receiving chemotherapy versus observation.
ER: estrogen receptor PR: progesterone receptor
| Table 1. Patient characteristics and comparison between those receiving chemotherapy versus observation | |||
| No Chemo N = 261 (62.6%) | Chemo N = 156 (37.4%) | p-value | |
| Age | <0.001 | ||
| <65 | 111 (53.9%) | 95 (46.1%) | |
| ≥65 | 150 (71.1%) | 61 (28.9%) | |
| Race | 0.136 | ||
| White | 202 (65.2%) | 108 (34.8%) | |
| Black | 50 (53.8%) | 43 (46.2%) | |
| Other | 9 (64.3%) | 5 (35.7%) | |
| Charlson-Deyo | 0.038 | ||
| 0 | 185 (59.1%) | 128 (40.9%) | |
| 1 | 58 (72.5%) | 22 (27.5%) | |
| ≥2 | 18 (75.0%) | 6 (25.0%) | |
| ER Status | 0.526 | ||
| ER- | 186 (61.0%) | 119 (39.0%) | |
| ER+ | 48 (67.6%) | 23 (32.4%) | |
| Unknown | 27 (56.9%) | 14 (34.1%) | |
| PR Status | 0.294 | ||
| PR- | 204 (62.6%) | 122 (37.4%) | |
| PR+ | 7 (46.7%) | 8 (53.3%) | |
| Unknown | 147 (65.0%) | 79 (35.0%) | |
| HER2Neu Status | 0.294 | ||
| HER2Neu- | 107 (60.8%) | 69 (39.2%) | |
| HER2Neu+ | 7 (46.7%) | 8 (53.3%) | |
| Unknown | 147 (65.0%) | 79 (35.0%) | |
| T-stage | 0.867 | ||
| T1 | 13 (61.9%) | 8 (38.1%) | |
| T2 | 40 (58.8%) | 28 (41.2%) | |
| T3 | 53 (63.1%) | 31 (36.9%) | |
| T4 | 90 (57.7%) | 66 (42.3%) | |
| N-stage | 0.183 | ||
| N0 | 86 (64.2%) | 48 (35.8%) | |
| N1 | 52 (51.5%) | 49 (48.5%) | |
| N2 | 29 (64.4%) | 16 (35.6%) | |
| N3 | 17 (53.1%) | 15 (46.9%) | |
| Site of Metastasis | |||
| Bone | 56 (57.1%) | 42 (42.9%) | 0.521 |
| Brain | 17 (70.8%) | 7 (29.2%) | 0.507 |
| Liver | 26 (52.0%) | 24 (48.0%) | 0.278 |
| Lung | 87 (63.5%) | 50 (36.5%) | 0.652 |
| Hormonal Therapy | 0.007 | ||
| No | 217 (60.8%) | 140 (39.2%) | |
| Yes | 35 (81.4%) | 8 (18.6%) | |
| Facility type | <0.001 | ||
| Non-academic | 191 (73.5%) | 69 (26.5%) | |
| Academic | 66 (46.2%) | 77 (53.8%) | |
| Region | 0.199 | ||
| Northeast | 48 (59.3%) | 33 (40.7%) | |
| Midwest | 68 (64.2%) | 38 (35.8%) | |
| South | 93 (61.2%) | 59 (38.8%) | |
| West | 48 (75.0%) | 16 (25.0%) | |
| Insurance | 0.053 | ||
| Not insured | 7 (53.8%) | 6 (46.2%) | |
| Private insurance | 98 (61.6%) | 61 (38.4%) | |
| Medicaid | 23 (47.9%) | 25 (52.1%) | |
| Medicare | 128 (68.8%) | 58 (31.2%) | |
| Other/unknown | 5 (45.5%) | 6 (54.5%) | |
| Income | 0.767 | ||
| < $38,000 | 41 (59.4%) | 28 (40.6%) | |
| $38,000-$47,999 | 60 (60.0%) | 40 (40.0%) | |
| $48,000-$62,999 | 68 (64.2%) | 38 (35.8%) | |
| ≥$63,000 | 87 (65.4%) | 46 (34.6%) | |
| Year of diagnosis | 0.446 | ||
| 2004-2007 | 56 (62.9%) | 33 (37.1%) | |
| 2008-2011 | 93 (66.4%) | 47 (33.6%) | |
| 2012-2015 | 112 (59.6%) | 76 (40.4%) | |